retatrutide mechanism of action retatrutide clinical trials 2024 2025 Retatrutide—A Game Changer in Obesity Pharmacotherapy ESC 2024: Retatrutide improves lipid

Research Limitations Current evidence has limitations

[DOI] [PubMed] [Google Scholar] 40.McGuire D, Van de Werf F, Armstrong P, et al

Over 2,000 participants at 129 center in 16 countries who injected weekly vs placebo for the trial lost 15% of their body weight compared to less than 3% with the placebo group

To qualify for these medications, per the FDA, patients must have: BMI 30, or BMI 27 with at least one weight-related condition, such as high cholesterol, high blood pressure, or Type 2 diabetes Wegovy has also been approved as an oral tablet for patients who prefer not to use an injection

Discard immediately

Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial